Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 3/2/2026 | $35.00 | Hold → Buy | Argus | |
| 2/25/2026 | $25.00 | Underperform | RBC Capital Mkts | |
| 2/20/2026 | $25.00 | Underweight | Barclays | |
| 2/12/2026 | $27.00 | Outperform → Neutral | Daiwa Securities | |
| 1/7/2026 | $25.00 | Neutral | UBS | |
| 12/2/2025 | $26.00 | Neutral | Citigroup | |
| 11/13/2025 | $30.00 | Sector Outperform | Scotiabank | |
| 4/22/2025 | $24.00 | Neutral | Cantor Fitzgerald |
4 - PFIZER INC (0000078003) (Issuer)
4 - PFIZER INC (0000078003) (Issuer)
3 - PFIZER INC (0000078003) (Issuer)
8-K - Arbutus Biopharma Corp (0001447028) (Filer)
DEFA14A - Arbutus Biopharma Corp (0001447028) (Filer)
DEF 14A - Arbutus Biopharma Corp (0001447028) (Filer)
For Immediate Release: October 25, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA updated the advisory for the outbreak of E. coli O157:H7. A specific ingredient has not yet been confirmed as the source of the outbreak, but most sick people report eating McDonald’s Quarter Pounder burgers. Investigators are working to deter
Submission status for PFIZER INC's drug HYMPAVZI (ORIG-1) with active ingredient MARSTACIMAB-HNCQ has changed to 'Approval' on 10/11/2024. Application Category: BLA, Application Number: 761369, Application Classification:
For Immediate Release: October 11, 2024 Today, the U.S. Food and Drug Administration approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors (neutralizing antibodies). “Today’s approval of Hympavzi pro
Fast Track designation has the potential to facilitate development and accelerate FDA review of imdusiran WARMINSTER, Pa., April 15, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company focused on infectious disease, today announced that the U.S. Food and Drug Administration ("FDA") has granted Fast Track designation for imdusiran for the treatment of chronic hepatitis B ("cHBV"). "We are excited about the potential of imdusiran, which in trials has achieved functional cure for 10 chronic hepatitis B patients to date and allowed many others to live medication-free, to address significant unmet medica
Pfizer Inc. (NYSE:PFE) announced today that its shareholders and the general public are invited to access its virtual 2026 Annual Meeting of Shareholders on Thursday, April 23, 2026, at 9:00 a.m. EDT. Shareholders can find information on accessing and registering for the virtual meeting at https://meetnow.global/PFE2026. On the day of the Annual Meeting, shareholders may begin logging into the virtual meeting platform at 8:45 a.m. EDT using either the control number found on their proxy card, voting instruction form or the notice that was previously received. Only shareholders who log into the meeting using a control number will have the ability to ask questions or vote during the live me
MELBOURNE, Australia and INDIANAPOLIS, April 09, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces two additional Non-Executive Director (NED) appointments, effective May 11, 20261, as part of Board expansion and succession planning: Maria Rivas, MD is an experienced public company board director and S&P 100 senior pharmaceutical executive with more than 25 years' experience in late-stage clinical development, commercialization and governance leadership. Dr. Rivas currently serves on the board of directors of The Cooper Companies, Inc. (NASDAQ:COO), a medical technology company, and also served as an independent director for Medidata
Argus upgraded Pfizer from Hold to Buy and set a new price target of $35.00
RBC Capital Mkts initiated coverage of Pfizer with a rating of Underperform and set a new price target of $25.00
Barclays initiated coverage of Pfizer with a rating of Underweight and set a new price target of $25.00
4 - PFIZER INC (0000078003) (Issuer)
4 - PFIZER INC (0000078003) (Issuer)
4 - PFIZER INC (0000078003) (Issuer)
Kfar Saba, Israel, March 04, 2026 (GLOBE NEWSWIRE) -- ParaZero Technologies Ltd. (NASDAQ:PRZO) (the "company" or "ParaZero"), an aerospace defense company pioneering smart, autonomous solutions for the global manned and unmanned aerial systems (UAS) industry, recently announced the appointment of Bat-Sheva Noy as its new Vice President of Global Sales. Ms. Noy brings more than 20 years of extensive commercial and leadership experience, with particular expertise in strategic planning, market access, and leading cross-functional teams. Most recently, from 2020 to 2025, she served as the Business Unit Lead for Rare Diseases at Pfizer Israel ((a subsidiary of Pfizer Inc., NYSE:PFE). In that
Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham
Voluntary agreement meets the President's four requests while also protecting the U.S. ecosystem responsible for America's leadership in delivering medical breakthroughs Agreement provides certainty from tariffs and clarity on pricing framework that furthers Pfizer's ability to expand investment in U.S.-based innovation and return manufacturing to the U.S. Pfizer to fully focus on delivering the next generation of cures, especially in cancer, obesity, vaccines, and inflammation and immunology Pfizer CEO Albert Bourla joins President Donald J. Trump and members of his Administration in White House event today Pfizer Inc. (NYSE:PFE) today announced a historic agreement with the T
Pfizer Inc. (NYSE:PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EDT on Tuesday, May 5, 2026. The purpose of the call is to provide an update on Pfizer's results, as reflected in the company's First Quarter 2026 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. Participants are advised to register in advance of the conference call. You can also listen to the conference
Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna's Section 1498 appealIf the $1.3 billion payment is realized, this settlement will be the largest disclosed patent settlement paid in the pharmaceutical industry and the second largest in any industrySettlement holds Moderna accountable for infringement and provides for the court to enter judgment of no invalidity on the four Genevant/Arbutus patents asserted in the caseGenevant grants Moderna a global non-exclusive license to its LNP delivery technology for SM-102-containing mRNA vaccines for infectious disease and a covenant not to sue for certain Geneva
Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna's Section 1498 appealIf the $1.3 billion payment is realized, this settlement will be the largest disclosed patent settlement paid in the pharmaceutical industry and the second largest in any industrySettlement holds Moderna accountable for infringement and provides for the court to enter judgment of no invalidity on the four Genevant/Arbutus patents asserted in the caseGenevant grants Moderna a global non-exclusive license to its LNP delivery technology for SM-102-containing mRNA vaccines for infectious disease and a covenant not to sue for certain Geneva
SC 13G/A - Arbutus Biopharma Corp (0001447028) (Subject)
SC 13G - Arbutus Biopharma Corp (0001447028) (Subject)
SC 13D/A - Arbutus Biopharma Corp (0001447028) (Subject)
